1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Short Bowel Syndrome Market
2.2. Global Short Bowel Syndrome Market, By Drug, 2023 (US$ Million)
2.3. Global Short Bowel Syndrome Market, By Geography, 2023 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2023

3. Short Bowel Syndrome Market: Competitive Analysis
3.1. Market Positioning of Key Short Bowel Syndrome Market Vendors
3.2. Strategies Adopted by Short Bowel Syndrome Market Vendors
3.3. Key Industry Strategies
4. Short Bowel Syndrome Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Short Bowel Syndrome Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Short Bowel Syndrome Market: By Drug, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. GLP-2
5.3.2. Glutamine
5.3.3. Growth Hormones
5.3.4. Other Drugs


6. North America Short Bowel Syndrome Market, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Short Bowel Syndrome Market: By Drug, 2022-2032, USD (Million)
6.3.Short Bowel Syndrome Market: By Region, 2022-2032, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Short Bowel Syndrome Market: By Drug, 2022-2032, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Short Bowel Syndrome Market: By Drug, 2022-2032, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Short Bowel Syndrome Market: By Drug, 2022-2032, USD (Million)

7. UK and European Union Short Bowel Syndrome Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Short Bowel Syndrome Market: By Drug, 2022-2032, USD (Million)
7.3.Short Bowel Syndrome Market: By Region, 2022-2032, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Short Bowel Syndrome Market: By Drug, 2022-2032, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Short Bowel Syndrome Market: By Drug, 2022-2032, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Short Bowel Syndrome Market: By Drug, 2022-2032, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Short Bowel Syndrome Market: By Drug, 2022-2032, USD (Million)
7.3.1.5. France
7.3.1.5.1. Short Bowel Syndrome Market: By Drug, 2022-2032, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Short Bowel Syndrome Market: By Drug, 2022-2032, USD (Million)

8. Asia Pacific Short Bowel Syndrome Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Short Bowel Syndrome Market: By Drug, 2022-2032, USD (Million)
8.3.Short Bowel Syndrome Market: By Region, 2022-2032, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Short Bowel Syndrome Market: By Drug, 2022-2032, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Short Bowel Syndrome Market: By Drug, 2022-2032, USD (Million)
8.3.1.3. India
8.3.1.3.1. Short Bowel Syndrome Market: By Drug, 2022-2032, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Short Bowel Syndrome Market: By Drug, 2022-2032, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Short Bowel Syndrome Market: By Drug, 2022-2032, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Short Bowel Syndrome Market: By Drug, 2022-2032, USD (Million)

9. Latin America Short Bowel Syndrome Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Short Bowel Syndrome Market: By Drug, 2022-2032, USD (Million)
9.3.Short Bowel Syndrome Market: By Region, 2022-2032, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Short Bowel Syndrome Market: By Drug, 2022-2032, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Short Bowel Syndrome Market: By Drug, 2022-2032, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Short Bowel Syndrome Market: By Drug, 2022-2032, USD (Million)

10. Middle East and Africa Short Bowel Syndrome Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Short Bowel Syndrome Market: By Drug, 2022-2032, USD (Million)
10.3.Short Bowel Syndrome Market: By Region, 2022-2032, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Short Bowel Syndrome Market: By Drug, 2022-2032, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Short Bowel Syndrome Market: By Drug, 2022-2032, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Short Bowel Syndrome Market: By Drug, 2022-2032, USD (Million)

11. Company Profile
11.1. Ardelyx, Inc.
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. Emmaus Life Sciences, Inc.
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. GLyPharma Therapeutic, Inc.
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. Merck KGaA
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. Naia Pharmaceuticals, Inc.
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. Nutrinia Ltd.
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. OxThera
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. Sancilio & Company, Inc.
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. Shire plc
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives
11.10. Zealand Pharma A/S
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Portfolio
11.10.4. Strategic Initiatives